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Summary
Cystic fibrosis (CF)-an autosomal recessive disorder
caused by mutations in CF transmembrane conductance
regulator (CFTR) and characterized by abnormal chlo-
ride conduction across epithelial membranes, leading to
chronic lung and exocrine pancreatic disease-is less
common in African-Americans than in Caucasians. No
large-scale studies of mutation identification and screen-
ing in African-American CF patients have been reported,
to date. In this study, the entire coding and flanking
intronic sequence of the CFTR gene was analyzed by
denaturing gradient-gel electrophoresis and sequencing
in an index group of 82 African-American CF chromo-
somes to identify mutations. One novel mutation,
3120+1G--A, occurred with a frequency of 12.3% and
was also detected in a native African patient. To estab-
lish frequencies, an additional group of 66 African-
American CF chromosomes were screened for mutations
identified in two or more African-American patients.
Screening for 16 "common Caucasian" mutations iden-
tified 52% of CF alleles in African-Americans, while
screening for 8 "common African" mutations accounted
for an additional 23%. The combined detection rate
of 75% was comparable to the sensitivity of mutation
analysis in Caucasian CF patients. These results indicate
that African-Americans have their own set of "com-
mon" CF mutations that originate from the native Afri-
can population. Inclusion of these "common" mutations
substantially improves CF mutation detection rates in
African-Americans.
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Introduction
Cystic fibrosis (CF) is the most common life-shortening
autosomal recessive disorder in Caucasians. Classically
affected patients manifest chronic sinopulmonary dis-
ease with pseudomonas infection, pancreatic exocrine
insufficiency, elevated sweat chloride concentrations,
and male infertility due to bilateral absence of the vas
deferens (Welsh et al. 1995; Cutting 1997). The reported
incidence in Caucasians has varied between 1/2,000 to
1/3,000 live births, depending on the population sam-
pled and the detection method used (Welsh et al. 1995).
The disease is caused by alterations in the CF transmem-
brane conductance regulator (CFTR), which functions
as a chloride channel and regulator of other channels in
epithelial cells (Welsh et al. 1995). The most common
mutation in CFTR is a deletion of 3 nt that lead to the
omission of phenylalanine at position 508 (AF508) and
is present on 67% of Caucasian CF chromosomes
worldwide (Cystic Fibrosis Genetic Analysis Consor-
tium 1994).
CF occurs in non-Caucasian populations but is much
less common than in the Caucasian population (Cutting
1997). Native Africans and native Asians with no
known Caucasian ancestors have been reported with the
classic form of the disease, indicating that CF alleles are
present in all racial groups (Levin et al. 1967; Wang et
al. 1968). The incidence of CF in African and Asian
populations is higher where considerable mixing has oc-
curred with Caucasians. For example, -1/15,300 indi-
viduals of African descent living in the United States is
born with CF (Hamosh et al., in press). The identifica-
tion of CF alleles in African-Americans that are common
in Caucasians indicates that the increased incidence of
CF is the consequence of genetic admixture with Cauca-
sians (Cutting et al. 1992; Ober et al. 1992). However,
admixture alone does not account for the occurrence of
CF in African-Americans. Haplotype studies and limited
mutation analysis suggest that the distribution of CF
mutations differs among African-Americans and U.S.
Caucasians (Cutting et al. 1989, 1990b, 1992). Further-
more, African-Americans carry CF mutations that have
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never been identified in Caucasian CF patients (Cutting
et al. 1992). It appears that the combination of Cauca-
sian CF alleles introduced by admixture and the presence
of CF alleles from the African population accounts for
the incidence of CF in African-Americans. Therefore,
analysis of this group of patients provides a powerful
tool to identify CF alleles derived from a population
where the disease is rare. To this end, a sensitive muta-
tion-detection technique was used to identify the vast
majority of CF mutations in an index group of African-
American CF patients. Additional patients were then
screened to establish frequencies of alleles observed
more than once in African-American patients. We have
discovered that African-Americans have their own sub-
set of "common" mutations that appear to be of African
origin. It is interesting that one mutation (3120+ 1A-+G)
accounts for about half of the African CF alleles. These
results further our understanding of the distribution of
CF alleles among human populations and facilitate the
development of more sensitive tests for CF mutation
analysis in African-Americans.
Patients, Material, and Methods
Patients
Blood samples for CFTR genotyping were collected
from 71 unrelated African-American patients. Six unre-
lated mixed-race patients (one African-American parent
and one Caucasian parent) were also studied. The index
group consisted of 39 African-American and 4 mixed-
race patients from 11 CF centers. Subsequently, two
independent groups were collected to screen for the fre-
quency of identified recurrent mutations. One group (17
African-Americans and 1 mixed-race patient) was ob-
tained from six CF Foundation-accredited centers, and
the other group (15 African-Americans and 1 mixed-
race patient) was collected through the University of
North Carolina at Chapel Hill. One DNA sample from
a native African CF patient from Cameroon was avail-
able for study (Demay et al. 1984).
Mutation Analysis
All patients were screened for the AF508 mutation
and 15 common Caucasian CF mutations using a reverse
dot strip hybridization system (Kawasaki et al. 1993)
(R117H, 621+1G--T, R334W, R347P, A455E, A1507,
1717-1G-+A, G542X, S549N, GSS1D, R553X, R560T,
3849+10kbC-+T, W1282X, and N1303K) (Welsh et al.
1995) and a deep intron 11 splice-site mutation,
1811+1.6kbA-+G (Chillon et al. 1995). In the index
group, samples without identified mutations were ana-
lyzed by denaturing gradient-gel electrophoresis
(DGGE) of the coding and flanking intronic sequences
of the CFTR gene as described elsewhere (Macek et al.
1997). Each electrophoretic variant detected by DGGE
was sequenced to identify specific mutations. Exon 9 of
CFTR was analyzed be sequencing only. Family studies
were performed for patients carrying novel mutations
to confirm independent assortment of the novel allele.
Parental genotypes were analyzed for mixed-race pa-
tients to determine which allele was inherited from the
African-American parent.
In the two independent African-American groups,
samples were screened for eight mutations that have
been identified in two or more African-American CF
patients, including 405+3A-+C (present study), 444delA
(White et al. 1991), G480C (Smit et al. 1995), R553X
(Cutting et al. 1990b), A559T (Cutting et al. 1990b),
2307insA (Smit et al. 1993), 3120+1G-+A (present
study), and S1255X (Cutting et al. 1990a). Screening
protocols for mutations 444delA, G480C, 2307insA,
and S1255X were previously reported in the references
cited in the preceding sentence. The A559T mutation
creates a unique MseI restriction site. Procedures for
allele - specific oligonucleotide hybridization (ASO)
screening for the 405+3A--C and 3120+1G-+A muta-
tions are described below.
A panel of 94 African-American individuals with no
family history of CF (188 normal CF chromosomes) and
13 African-American parents of a CF patient (13 non-
CF chromosomes) were used as a control group for ASO
screening of novel missense and splice-site mutations.
An additional panel of 80 Caucasian CF patients (160
CF chromosomes), who were subjected to DGGE analy-
sis simultaneously with the index group, were used to
verify the racial derivation of novel African-American
CF alleles. ASO screening was performed as described
by Cutting et al. (1992). Primer sequences and final wash
temperatures for each ASO are indicated in table 1.
The 3120+1G-+A mutation can be detected by a PCR-
mediated site-directed mutagenesis assay (Friedman et
al. 1991) by use of primer 3120+1G-A REV/MIS:
5'- CTITAACGGTACTTA7F-IT-IIACAGA-3' and primer
16i-5' (Zielenski et al. 1991b) annealing at 51'C. Diges-
tion with BglII generates DNA fragments of 341 and 26
bp when the 3120+1G-*A mutation is present.
Results
Analysis of the entire coding region identified putative
disease-producing mutations in 79 (96%) of the 82
African-American CFTR genes in our index group. The
common mutation in Caucasians, AF508, was the most
frequently observed mutation in African-Americans, ac-
counting for 36 (44%) of the alleles. We discovered
another common mutation, 3120+1G-1A, in 10 pa-
tients, (12%) which was also detected in the native Afri-
can, suggesting it originated in that population. Four
other mutations were observed more than once in the
index group (405+3A--C [2], R553X [3], A559T [2],
and S1255X [2]). Twelve novel mutations were identi-
fied in one patient each: W19C, 621G--*A, 1002-3T-*G,
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Table 1
Novel CFTR Mutations Identified in This Study, in African-American CF Patients
Mutation Nucleotide Change Exon/Intron Consequence Location Screening Method
1 W19C G-OT at 189 Exon 2 Trp-Cys at 19 ... Loss of AvaII; ASO
2 405+3A-C A-C at 405+3 Intron 3 Splice mutation TM 1 ASO
3 621G-A G-IA at 621 Exon 4 Splice mutation ... ASO
4 1002-3T-G T-G at 1002-3 Intron 6B Splice mutation ... ASO
5 1119delA delA at 1119 Exon 7 Frameshift ... Direct sequencing
6 G330X G-OT at 1120 Exon 7 Gly-+Stop at 330 ... Direct sequencing
7 S364P T-C at 1222 Exon 7 Ser-Pro at 364 ... Loss of Hinfl; ASO
8 1504delG deIG at 1504 Exon 9 Frameshift NBF I Loss of BamHI
9 Y563D T-OG at 1819 Exon 12 Tyr-Asp at 563 NBF I Loss of XcaI; ASO
10 1618T T-IC at 1985 Exon 13 Ile-'Thr at 618 R Loss of VspI or AsuI; ASO
11 R764X C-T at 2422 Exon 13 Arg-Stop at 764 R Direct sequencing
12 2734delG/insAT delG/insAT at 2734 Exon 14A Frameshift TM 7 Creates VspI or Pad
13 3120+1G-A GI-A at 3120+1 Intron 16 Splice mutation TM 9 Loss of BstNI
14 3791delC delC at 3791 Exon 19 Frameshift ... Direct sequencing
NoTE. -TM indicates transmembrane segment; NBF denotes nucleotide binding fold; and R indicates regulatory domain of CFTR. Oligonucle-
otides for allele-specific oligonucleotide (ASO) hybridization screening of novel African-American CF mutations are as follows: W19C, 5'-FI-TI
TAG CTG TAC CAG ACC A-3' (final wash [FW] at 510C); 405+3 A-C, 5'-ATT TAG GGG TCA GGA TCT-3' (FW at 530C); 621 G-IA,
5'-TTG ATT TAT AAG AAA GTA ATA CTT-3' (FW at 54'C); 1002-3 T- G, 5'-GTT CTG TTC TAT AAA AAA CAA-3' (FW at 53'C);
S364P, 5'-GTA TGA CCC TCT TGG-3' (FW at 450C); Y563D, 5'-TCA TCT TTG TCT ACT GAG AG-3' (FW at 510C); and I618T, 5'-CAA
AAT ATFT AAC TlT- GCA TGA A-3' (FW at 520C).
1119delA, G330X, S364P, 1504delG, Y563D, 1618T,
R764X, 2734delG/insAT, and 3791delC (table 1). Of
these, only W19C occurred in a pancreatic-sufficient pa-
tient. DNA from normal individuals was screened to
evaluate whether any novel mutation was a neutral vari-
ant. The 405+3A-)C mutation was observed once in
the panel of normal African-American CF chromosomes
from individuals without a family history of CF. Finally,
13 mutations found in one patient each had been pre-
viously reported in Caucasian patients (Q98R, R352Q,
V520F, 1812-1G--A, G542X, S549N, and Y913C)
(Romey et al. 1995; Welsh et al. 1995) or in African-
American patients (444delA, G480C, 1342-2delAG
[originally reported as 1342-1G--+C], 2307insA,
3662delA, and W1316X) (Cutting et al. 1990b; White
et al. 1991; Zielenski et al. 1991a; Smit et al. 1993,
1995).
There was one patient in whom neither mutation
could be identified: a pancreatic-sufficient 27-year-old
male with nasal polyposis, mild pulmonary disease
(forced expiratory volume in 1 min 92% predicted) and
an elevated sweat chloride concentration (88 mM and
112 mM, on two occasions). Although he was consider-
ably older at the time of diagnosis than most patients
(8 years 11 mo), his clinical findings are entirely consis-
tent with the pancreatic-sufficient form of the disease.
The third unidentified mutation occurred in a 15-year-
old boy with the classic form of the disease (pancreatic
insufficiency and elevated sweat chloride concentration).
He carried the frameshift mutation 3662delA in his
other gene.
To further establish the distribution of CF mutations
in African-Americans, we analyzed two additional
groups of patients. One group (15 African-Americans
and 1 mixed-race patient) attended the CF Clinic at the
University of North Carolina, and the other (17 African-
Americans and 1 mixed-race patient) was referred by
CF clinics across the United States. Each individual was
screened for 16 "common Caucasian" mutations and 8
mutations that had been observed in two or more Afri-
can-American patients (see Patients, Material, and
Methods). The distribution of mutations in the two
screening groups was similar to our index group. The
AF508 mutation was the most frequent (53%), followed
by 3120+1G--A (12%) with "common Caucasian" mu-
tations and "common African-American" mutations ac-
counting for 6% each. Altogether, 77% of mutations
were identified in these two groups of African-American
CF patients. When the index and two screening groups
were combined, screening for the 16 "common Cauca-
sian" and 8 "common African-American" mutations
identified 111 (75%) of the 148 African-American
CFTR genes studied (table 2). This detection rate is com-
parable to the efficiency of screening Caucasian patients
for common CF mutations (79%).
Discussion
This is the most comprehensive analysis of CF muta-
tions in African-Americans, to date. As suggested by
earlier studies, the overall distribution of mutations dif-
fered from U.S. Caucasians. The most common muta-
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Table 2
Distribution of CF Mutations in African-American and U.S.-Caucasian CF Patients
African-American U.S. Caucasiana
Mutation (n= 148) % (n = 8,714) %
Caucasian mutations:
AF508 71 48 5,769 66.2
R117H 0 0 47 .5
621+1 G--T 0 0 68 .8
R334W 1 .7 7 .1
R347P 0 0 24 .3
A455E 0 0 5 .1
AI507 1 .7 10 .1
1717-1 G-IA 1 .7 39 .5
G542X 1 .7 204 2.3
S549N 1 .7 4 .1
GS51D 1 .7 173 2.0
R553X (Caucasian)b 0 0 87 1.0
R560T 0 0 16 .2
3849+10kb C-T 0 0 51 .6
W1282X 0 0 235 2.7
N1303K 0 0 116 1.3
Subtotal 77 52 6,855 78.7
African-American mutations:
405+3 A-C 2 1.4 ... ...
444delA 1 .7 ... ...
G480C 2 1.4 ... ...
R553X (African)b 3 2.0 ... ...
A559T 3 2.0 ... ...
2307insA 3 2.0 ... ...
3120+1 GC-A 18 12.2 ... ...
S1255X 2 1.4 ... ...
Subtotal 34 23 ... ...
Total 111 75.0 6,855 78.7
NOTE.-Percentages are rounded. "n" refers to the number of chromosomes analyzed.
a U.S. Caucasian data were derived from data reported to the CF Genetic Analysis Consortium (1994).
bThe R553X mutation was included in each group of common mutations, since it has arisen independently
in the Caucasian and African populations on different chromosome backgrounds (Reiss et al. 1991).
tion in Caucasians, zXF508 (66%), was also the most
common in African-Americans (48%). This observation
was consistent with smaller studies of African-American
patients in the southeastern United States (50%) and the
Chicago area (25%) (Ober et al. 1992; Phillips et al.
1995). Several mutations belonging to a subset of CF
alleles that occur in common among Caucasians were
discovered in the African-American patients. Like
AF508, the presence of these mutations in African-
Americans was likely the result of Caucasian admixture.
This subset accounts for -13% of Caucasian CF alleles
but was responsible for a much smaller fraction of Afri-
can-American CF mutations (4%).
Fourteen novel mutations discovered in this study are
predicted to be disease producing. Six mutations intro-
duce a premature termination codon either by frameshift
or single nucleotide substitution. The deleterious conse-
quence of this type of alteration on CFTR gene expres-
sion has been well documented (Hamosh et al. 1991;
Smit et al. 1993; Will et al. 1995). Four mutations are
predicted to alter RNA splicing. Three changes occur at
nucleotides within the consensus sequence for splice-
donor sites: the last nucleotide of exon 4 (621G-+A)
and in nucleotides at the +1 (3120+1G-+A) and +3
(405+3A--C) positions of splice-donor sites in introns
16 and 3, respectively. Nucleotide substitutions at each
of these positions have been shown to alter RNA pro-
cessing of human genes (Krawczak et al. 1992). The
405+3 A-RC mutation, found twice in CF patients, was
also present in one CFTR gene from a healthy African-
American. This finding might suggest that the 405+3
mutation is a neutral polymorphism. However, we be-
lieve that this mutation is deleterious for the following
reasons. Analysis of splice-donor sites reveals that ade-
nine is most common (60%) at the +3 position, fol-
lowed by guanine (32%), while cytosine is the least com-
mon (3%) (Padgett et al. 1986). Second, mutation at
this location has been shown to affect RNA splicing in
a model system (Montell and Berk 1984). Finally, there
are five reports of mutations at this location (G-+T[ 2],
1125
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G--C [1], and A-GG [2]) causing aberrant RNA splicing
(Krawczak et al. 1992; Mertes et al. 1994; Brackett et
al. 1995). Together, these observations indicate that it
is likely that the 405+3 A-RC mutation will affect CFTR
mRNA splicing and suggest that the individual in the
general population with this mutation is a carrier of a
deleterious CF allele. The other splice-site mutation is a
transversion at the -3 position of the splice-donor site;
a location that is highly conserved and, when altered, is
associated with aberrant splicing in a number of genes
(Krawczak et al. 1992). The remaining four mutations
are amino acid substitutions. None of these alterations
were found on 180 normal or 13 non-CF chromosomes
from African-Americans, indicating that these mutations
are not polymorphisms.
Screening for mutations that had been observed in
two or more patients in this study and for mutations
identified in one patient that had been previously re-
ported in African-American CF patients revealed that
African-Americans have their own subset of "common"
mutations. As a group, these mutations occur at a fre-
quency comparable to the subset of "common Cauca-
sian" mutations (excluding AF508). The "common Afri-
can" mutations were not observed in any Caucasian
chromosomes, suggesting that they are derived from
the African population. It is interesting that the
3120+1G-A mutation is quite frequent among African-
Americans. If Caucasian alleles were excluded, the
3120+1G--A mutation would account for 53% of Afri-
can-American CF alleles. The high frequency of
3120+l1G--A might be the result of a founder effect
in the African-American population. However, a small
study of native Africans living in South Africa discovered
the 3120+1G-*A mutation in four of six CFTR genes
(Caries et al. 1996). Therefore, despite the apparent rar-
ity of CF in Africa, the 3120+1G--A mutation may not
be a rare allele in native Africans. It is plausible that CF
may be underdiagnosed in native Africans, since failure
to thrive and diarrhea due to CF can be difficult to
distinguish from more common causes such as viral in-
fection and malnutrition.
The discovery that a small number of mutations ac-
count for a significant fraction of CF alleles will simplify
mutation screening in African-Americans. Similar find-
ings have been made in geographically or ethnically dis-
tinct groups of Caucasians. The vast majority of CF
alleles in Ashkenazi Jews can be detected by screening
for five mutations (Abeliovich et al. 1992). Screening for
-20 mutations enables mutation sensitivity to exceed
90% for Celts living in Brittany, France, and for Belgian
Caucasians (Ferec et al. 1992; Mercier et al. 1993). Sub-
sets of "common" CF alleles do occur in more diverse
populations such as U.S. Caucasians but account for a
smaller fraction of all CF alleles. Consequently, muta-
tion screening for AF508 and the "common" alleles de-
tects -79% of CF mutations in U.S. Caucasians (Cystic
Fibrosis Genetic Analysis Consortium 1994). This study
indicates that similar rates of CF mutation detection
can be achieved in African-Americans by including the
"common African" CF alleles.
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